Product vision
  • Intermittent preventive treatment (TPP-1) and prophylaxis (TPP-2)
  • Interfere with two pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication
  • Atovaquone acts against P. falciparum via inhibition of mitochondrial electron transport
Key features
  • Liver-stage activity and prophylactic efficacy
  • Lower doses of atovaquone required in the combination leading to lower cost of goods
  • To obtain comparable bioavailability
  • Relative bioavailability study between atoguanil and atovaquone-proguanil to be set-up
Next milestone
  • Initiate bioavailability study
MMV Project Director
  • Dr Isabelle Borghini Fuhrer